Drug intelligence / Profile preview

GF-4001

Development stage: Preclinical
Lead developer: GenFlow Biosciences
Modality: AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies
Administration: Intravenous

Overview

GF-4001 is a non-human (veterinary) version of the anti-aging gene therapy GF-1002, developed by Genflow Biosciences. It is designed for use in dogs and utilizes an adeno-associated viral (AAV) vector to deliver a variant of the Sirtuin 6 (SIRT6) gene found in centenarians. The therapy aims to improve DNA maintenance and delay age-related diseases by providing additional copies of this longevity-associated gene. Unlike human-targeted versions, GF-4001 is specifically formulated for veterinary applications[3][4].

Targets

SIRT6 (NAD-dependent protein deacetylase sirtuin-6)

Beyond the preview

Go deeper on GF-4001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GF-4001.

Explore the full profile